Heart Health in China: The Chinese Cardiovascular Market (2026)

I’m Philip Chen, CEO of GMA. I’ve spent over a decade helping foreign health and wellness brands find their footing in China, and heart health is one of the fastest moving corners of that market right now.

China has more than 1.4 billion people, and its cardiovascular health picture is changing fast. Thirty years of economic growth brought more meat, more sugar, less walking, and more stress to daily life. Heart disease is now the top cause of death in the country, and the market for cardiovascular products keeps growing with it.

The China cardiovascular devices market alone sits around USD 3.2 billion in 2025 and is expected to reach close to USD 4.2 billion by 2030. The drug side of the market is following a similar curve, heading toward roughly USD 3.7 billion by 2026. If you sell anything connected to heart health, from devices to supplements to wearables, China is a market you cannot ignore.

In this updated guide, I’ll walk you through what changed going into 2026: an aging population that needs heart care more than ever, the rise of health wearables like the Huawei Watch, the growing functional food and supplement space, and how foreign brands can market cardio products the right way, without running into trouble with health claim rules.

Why China’s Heart Problem Keeps Growing

Cardiovascular disease (CVD) is not slowing down in China. The National Center for Cardiovascular Diseases, working under the National Health Commission (国家卫健委), published its 2024 report on the topic, and the numbers are big: around 330 million people in China now live with some form of cardiovascular disease. That includes 245 million people with high blood pressure, 13 million stroke patients, and close to 9 million people with heart failure.

Doctors also found that 80.5% of Chinese adults carry at least one risk factor for heart disease. That figure has barely moved since our last update, and it won’t move much until diet and activity habits shift at a national scale.

Three things keep pushing this number up: richer diets with more salt, sugar, and oil, more sedentary urban jobs paired with long work hours, and a population that is aging quickly. That last point is the one most foreign brands underestimate.

An Aging Population Changes the Math

By 2040, China will have around 402 million people aged 60 and older, about 28% of the entire population. Right now, roughly 75% of Chinese seniors already live with a chronic condition such as heart disease, diabetes, or high blood pressure. Heart failure cases in the country have doubled since 2000, and now sit near 12.1 million.

This matters for your brand because the buyer is changing. It’s not only middle-aged patients anymore. It’s their adult children buying monitors and supplements for aging parents, and it’s seniors themselves, many of whom are now perfectly comfortable shopping and paying with their phone. We covered this shift in more depth in our piece on China’s silver economy, and heart health is one of the biggest categories inside it.

Wearables Are Changing How China Watches Its Heart

One of the biggest shifts since our last update isn’t a drug or a device sold in hospitals. It’s the watch on people’s wrists.

Huawei’s Watch D2 is registered in China as a Class II medical device. It can take a single blood pressure reading or run a full 24 hour ambulatory monitoring cycle, the kind of test that used to mean a clinic visit. Huawei already sold more than a million units of the earlier Watch D worldwide, and the D2 is now live in China alongside the UK and EU.

This is not a small trend. Chinese market research firm 智研咨询 (Zhiyan Consulting) tracked strong growth in China’s smart watch category through 2025, with products offering blood pressure, heart rate, and ECG monitoring making up more than 65% of sales. Watches carrying medical grade certification grew more than twice as fast as ordinary fitness trackers over the same period.

What this means for your brand: a wearable is not your competitor if you sell a heart health product, it’s a lead generation channel. A shopper who gets a high blood pressure alert on their watch is exactly the person who searches for a solution five minutes later. Brands that build content and product bundles around that moment are winning attention cheaply.

The Rules You Need to Know: NMPA and Health Claims

The China National Medical Products Administration, or NMPA, regulates both medical devices and drugs, and the review path depends on classification. Medical devices fall into three classes. Class I is low risk, think a simple heart rate strap. Class III is high risk, things like pacemakers or heart valve replacements, and it goes through the toughest review. Approval can take anywhere from 6 months to a few years, so plan your market entry timeline with that range in mind.

Supplements and functional foods sit in a different lane entirely. They fall under China’s Food Safety Law and typically need what people call a 蓝帽子 (blue hat) registration, named after the small blue hat logo printed on approved health food packaging. Getting this mark means regulators reviewed your product and cleared it to be sold as a health food in China. For a deeper look at how this plays out across the wider health sector, see our guide on marketing medical, pharmacy, and health care products in China.

Compliance note: this article is marketing guidance, not medical or legal advice. Any claim that a product treats, prevents, or cures a disease, including heart disease, is heavily restricted in China and can get your ads pulled or your store account suspended. Words like “lowers blood pressure” or “treats arrhythmia” belong to registered drugs, not supplements or wearables. Always check your claims with a local regulatory consultant before you publish anything in the Chinese market.

Hospital, Private Clinic, or Straight to Consumer?

Foreign heart health brands usually pick one of three doors into China.

Public hospitals. This is where most Class II and Class III devices land first, because doctors need to trust a product before they prescribe or implant it. Getting here means running clinical trials inside China and working through slow, relationship heavy sales cycles with hospital procurement teams.

Private and specialty clinics. Faster to move, and increasingly popular with wealthier, health conscious patients who want shorter wait times and English speaking staff. This channel fits well for premium devices, monitoring services, and screening packages.

Direct to consumer. This is where wearables, monitoring apps, and most supplements live. Sales happen on Tmall, JD Health, and Douyin, backed by KOL doctors (real, licensed physicians who post health education content) explaining your product in plain language. It’s the fastest channel to test demand, and the one most foreign brands should start with before chasing a hospital contract.

Which Major Drugs Dominate the Chinese Cardiovascular Market?

The table below still reflects the core players in prescription heart medication. Competition from domestic Chinese generics keeps pushing on price, so expect thin margins if you enter through this channel.

Medical Devices and Procedures

Here is a table of commonly used cardiovascular devices and what they do:

A few real patterns still work well for device and drug brands entering China in 2026:

• A hypertension drug that partnered with pharmacies and physicians to run in store education days captured 10% category share within three months.
• A stent maker that ran hospital training workshops and built a peer network for cardiologists got adopted by several leading hospitals within its first year.

The lesson hasn’t changed: whoever moves first with a strong local partner and useful information for doctors wins the room, not necessarily the brand with the biggest ad budget.

Functional Food and Supplements for Heart Health in 2026

Supplements remain one of the easiest ways for a foreign heart health brand to enter China, and the category keeps growing. China’s broader health functional food market is on track to reach roughly 436.6 billion yuan in 2026, growing around 5.8% a year since 2022. Inside that space, heart health supplements specifically, things like CoQ10, omega-3, and plant sterols, sit in a fast moving segment forecast to grow close to 29% a year globally through 2035, with Asia Pacific, led by China, driving a big share of that growth.

Older Chinese consumers are still the core buyers here. Taking a supplement does not cure heart disease, a point worth repeating in your own marketing given the compliance note above, but it’s part of daily wellness routines for millions of households, especially where a parent or grandparent lives with high blood pressure or high cholesterol.

What changed since our last update: livestream selling now drives a big share of supplement discovery. Douyin and Xiaohongshu (also known as RedNote) are often where Chinese shoppers first hear about a new heart health supplement, usually from a doctor KOL doing a short, simple explainer, before they ever search for it on Tmall. If your brand only has a storefront and no short video presence, you’re missing where the buying decision actually gets made.

For more on the wider category, we cover Tmall and JD.com strategy in our guide on selling health supplements in China.

Where Does Traditional Chinese Medicine Fit In?

Traditional Chinese Medicine, or TCM, still runs alongside Western treatment for heart disease across the country, and that isn’t changing anytime soon. Many patients believe TCM causes fewer side effects, and a growing number of hospitals now offer both approaches side by side, a practice sometimes tied to the older TCM idea of 治未病, roughly “treating illness before it starts.”

Shenfu injection is a good example. It started as a TCM treatment for heart failure and is now also used in acute myocardial infarction care in some hospitals, part of a broader effort to blend TCM with Western emergency cardiology.

If you sell a Western product, don’t treat TCM as competition to fight. A message like “works well alongside your regular health routine” lands better in China than one that positions your brand against TCM.

Why Some Chinese Patients Still Look Abroad

Around 60,000 Chinese heart patients travel overseas each year for treatment, mainly due to trust gaps in domestic care, long wait times, and a wish for the newest technology. This is a smaller opportunity than it was five years ago, since domestic hospitals have closed some of that gap through foreign device partnerships, but it hasn’t disappeared. If your brand runs a clinic or hospital abroad, positioning around advanced technology and shorter wait times still resonates with this audience.

A Quick Case Study: How One Supplement Brand Grew in China’s Heart Health Space

A European CoQ10 and omega-3 supplement brand we worked with, let’s call them VitaCor to keep things anonymous, came to us wanting to enter the heart health category in China.

The approach: instead of launching straight on Tmall, we started with three licensed cardiologist KOLs on Douyin who create short, simple health education videos. Each video covered one everyday heart risk, a salty diet, poor sleep, sitting too long at a desk, and linked it back to the brand’s product as one small part of a daily routine, never as a treatment. We paired this with a WeChat mini-program quiz that gave users a simple heart risk score and a personalized supplement suggestion at the end.

The result: within four months, the brand’s monthly sales on its Tmall flagship store grew to almost three times its starting baseline, and over half of new customers came through the WeChat quiz funnel rather than direct search. No medical claims appeared anywhere in the campaign, only education and product fit.

How to Market Heart Health Products in China

• Know your audience. Are you selling to aging parents’ adult children, to seniors buying for themselves, or to younger, prevention minded shoppers? The message changes for each group.
• Partner with local distributors who already understand the regulatory environment, culture, and language of the Chinese market.
• Use Douyin, WeChat, and Xiaohongshu with real doctor KOLs, not just influencers, to build trust around a sensitive health topic.
• Look at wearable data partnerships. A watch that flags a health risk is a natural entry point into your product story.
• Watch your pricing and quality signals. Chinese buyers are price sensitive but also treat quality assurance as a dealbreaker in health categories.

Common Questions Foreign Brands Ask Us

Can I market my heart health supplement as something that lowers blood pressure?
No, not directly. Under Chinese health food rules, a supplement cannot claim to treat, prevent, or lower a specific medical condition. That kind of language is reserved for registered drugs. You can talk about supporting general wellness, energy, or a healthy daily routine, but any wording that sounds like a medical claim can get your listing removed or your ad account flagged. Work with a local regulatory reviewer before you finalize packaging or ad copy.

Do I need a hospital partner to sell a cardiovascular device in China?
It depends on the device class. High risk Class III devices, like pacemakers or valve replacements, almost always need hospital adoption and clinical trial data inside China before doctors will use them. Lower risk monitoring devices and consumer facing wearables can often go direct to consumer through Tmall, JD Health, or Douyin without ever touching a hospital procurement process.

Are wearables like the Huawei Watch a threat to my supplement or device brand?
We don’t see it that way. A wearable that flags high blood pressure or an irregular heartbeat creates a moment where the user is actively looking for a next step, whether that’s a supplement, a clinic visit, or a monitoring device. Smart brands build content and offers around that exact moment instead of treating wearable makers as competitors.

Sources

• 国家心血管病中心（受国家卫生健康委员会委托）,《中国心血管健康与疾病报告2024》概要, nccd.org.cn
• 智研咨询,《2026年中国智能手表行业发展现状及市场规模分析》, chyxx.com

We are your local partner in China!

China’s cardiovascular market keeps growing on the back of an aging population, more disease awareness, and a new generation of health tech. Whether you sell a supplement, a monitoring device, or a full cardiovascular product line, the opportunity is real, but so are the compliance rules around it.

GMA is a China based marketing agency helping foreign health and wellness brands enter this market the right way. Our team combines Chinese and foreign experts who know the regulatory side and the marketing side, so your brand doesn’t have to choose between moving fast and staying compliant.

Don’t hesitate to leave us a comment or contact us, so we can schedule a free consultation with one of our experts, who will learn about your brand and present the best strategy for your China market entry.